Chimeric antigens comprising extracellular domain of PD-L1

A chimeric antigen comprising an extracellular domain of Ligand 1 (PD-L1) of the human programmed cell death protein receptor, and the extracellular domain forming a multimer having a reduced binding capacity to the PD-1 receptor and the CD80 receptor compared to the native form of PD-L1. Also disclosed is a pharmaceutical composition comprising the chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant. The invention also discloses application of the chimeric antigen in preparation of a medicament for treating cancer or metastasis thereof. Also disclosed is a method of treating cancer or metastasis thereof in a subject in need thereof, characterized by administering a therapeutically effective amount of a pharmaceutical composition comprising the chimeric antigen described herein. 嵌合抗原，其包含人程序性细胞死亡蛋白受体的配体1(PD-L1)的胞外结构域，并且所述胞外结构域形成对PD-1受体和CD80受体具有相比PD-L1的天然形式降低的结合能力的多聚体。本发明还公开了包含所述嵌合抗原和至少一种药学上可接受的疫苗佐剂的药物组合物。所述嵌合抗原在制备治疗癌症或其转移的药物中的用途。本发明还公开了治疗有需要的个体中的癌症或其转移的方法，其特征在于施用治疗有效量的包含本文所述嵌合抗原的药物组合